HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
OC-TR monoclonal antibody (OC-TR)
a bispecific monoclonal antibody; level of anti-mouse-antibody response induced by MAb OC/TR in ovarian carcinoma patients is associated with longer survival
Also Known As:
OC-TR
; MAb OC-TR; monoclonal antibody OC-TR
Networked:
16
relevant articles (
2
outcomes,
3
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Amino Acids, Peptides, and Proteins: 1
Proteins: 484843
Blood Proteins: 12459
Serum Globulins: 553
Immunoglobulins: 30480
Antibodies: 133716
Bispecific Antibodies: 968
OC-TR monoclonal antibody: 16
Immunoproteins: 43
Immunoglobulins: 30480
Antibodies: 133716
Bispecific Antibodies: 968
OC-TR monoclonal antibody: 16
Globulins: 3062
Serum Globulins: 553
Immunoglobulins: 30480
Antibodies: 133716
Bispecific Antibodies: 968
OC-TR monoclonal antibody: 16
Related Diseases
1.
Carcinoma (Carcinomatosis)
02/01/1994 - "
In a comparative study we investigated the therapeutic efficacy of OV-TL 3/CD3 and OC/TR by targeting activated PBL with the bs-mAbs against intraperitoneally growing NIH:OVCAR-3 human ovarian carcinoma cells.
"
11/01/1997 - "
Clinical trials of patients with ovarian carcinoma with the OC/TR mAb have shown some complete and partial responses.
"
02/19/1999 - "
Evaluation of the anti-idiotypic response in HAMA-positive sera indicated that 11/17 sera showed high-titer (>6000) binding of OC/TR, as evaluated by a specific radioimmunoassay, and 15/18 and 16/16 sera specifically inhibited the binding of the MOv18 and anti-CD3 parental MAbs to ovarian-carcinoma cells and T lymphocytes respectively.
"
02/19/1999 - "
Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival.
"
11/01/1997 - "
Two patients with ovarian carcinoma treated with F(ab')2 fragments of the murine OC/TR developed distinct HAMA titers, which were mainly anti-idiotypic and only partly directed against the murine antibody constant regions.
"
2.
Neoplasms (Cancer)
12/01/1996 - "
Activation and antitumor activity were also observed, albeit to a lesser extent, using OC/TR and monospecific bivalent anti-CD28 mAb. In vitro analysis demonstrated that cross-linking between tumor and effector cells for at least 24 h was needed to achieve T-cell activation and development of antitumor activities.
"
08/19/1993 - "
The bi-specific MAbs alpha T3/OC2 and alpha OC/TR (both being combinations of MOv18 and alpha CD3) have been shown to lyse ovarian tumor cells in vitro.
"
09/15/1988 - "
In the perspective of in vivo tumor immunotherapy, as an alternative to cytotoxic T lymphocytes (CTL) from T-cell clones, since human peripheral blood mononuclear cells (PBMCs) without stimulation were quite ineffective, a suitable in vitro activation method was developed to render PBMCs lytic for relevant targets in the presence of the bispecific hybrid MAb alpha OC/TR.
"
02/01/1994 - "
No significant difference in survival was found between the OC/TR or OV-TL 3/CD3 bispecific antibody, although MOv18 expression was higher on NIH:OVCAR-3 ascites cells and PBL targeted with OC/TR induced slightly higher tumor cell lysis in vitro.
"
10/09/1997 - "
Thus, locoregional OC/TR-re-targeted cellular immunotherapy resulted in substantial local immunomodulation and anti-tumor effects but virtually no systemic immunomodulation.
"
3.
Ascites
02/01/1994 - "
No significant difference in survival was found between the OC/TR or OV-TL 3/CD3 bispecific antibody, although MOv18 expression was higher on NIH:OVCAR-3 ascites cells and PBL targeted with OC/TR induced slightly higher tumor cell lysis in vitro.
"
02/01/1994 - "
The efficacy of OV-TL 3/CD3 was compared to OC/TR with respect to tumor-associated antigen (TAA) binding on NIH:OVCAR-3 ascites cells and NIH:OVCAR-3 tumor cell lysis in vitro.
"
4.
Ovarian Neoplasms (Ovarian Cancer)
05/16/1996 - "
Five patients suspected of ovarian cancer received 123I-OC/TR F(ab')2 i.v. Unexpectedly, the first patient developed side effects (grade III-IV toxicity) starting 30 min after infusion (p.i.) of 1 mg of OC/TR F(ab')2. After approval of the Ethical Committee, the study was continued at lower dose levels (0.1 mg; 0.2 mg).
"
12/01/1994 - "
Purification of bispecific F(ab')2 from murine trinoma OC/TR with specificity for CD3 and ovarian cancer.
"
09/01/1995 - "
Tumour targeting of the anti-ovarian carcinoma x anti-CD3/TCR bispesific monoclonal antibody OC/TR and its parental MOv18 antibody in experimental ovarian cancer.
"
01/01/1992 - "
A bispecific monoclonal antibody (bs-MAb) (OC/TR) was produced in large quantities for the intraperitoneal (i.p.) treatment of ovarian cancer.
"
02/01/1994 - "
Immunotherapy in a human ovarian cancer xenograft model with two bispecific monoclonal antibodies: OV-TL 3/CD3 and OC/TR.
"
5.
Necrosis
05/16/1996 - "
The cytokines tumour necrosis factor-alpha, interferon-gamma and interleukin-2 showed maximum serum concentrations 2 h p.i. Tumour uptake ranged from 0.8 to 1.9% ID/kg, resulting in tumour/background ratios of 3 to 8. Our results suggest that at higher antibody dose levels OC/TR F(ab')2 causes T-cell activation with acute release of cytokines.
"
Related Drugs and Biologics
1.
Folic Acid (Vitamin M)
2.
Carrier Proteins (Binding Protein)
3.
Antigens
4.
OC-TR monoclonal antibody (OC-TR)
5.
Monoclonal Antibodies
6.
MOv18 monoclonal antibody
7.
Bispecific Antibodies
8.
Cytokines
9.
T-Cell Antigen Receptors (T-Cell Receptor)
10.
Interleukin-2 (IL2)
Related Therapies and Procedures
1.
Immunotherapy
2.
Intravenous Administration
3.
Immunomodulation